Cipla Limited

NSE:CIPLA.NS

Sector

🏥 Health Care

Industries

💊 Pharmaceuticals

🔬 Clinical Trials

💊 Drugstores & Retail Pharmacies

Location

India

Market Cap

USD 14.30 B

Share Price

USD 17.67

Avg Daily Volume

1,651,707

Change (1 day)

0.68%

Change (1 year)

-0.06%

Change (YTD)

-1.06%

Cipla Limited Free Cash Flow for the year ending March 31, 2025: USD 449.69 M

Cipla Limited Free Cash Flow is USD 449.69 M for the year ending March 31, 2025, a 34.70% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Cipla Limited Free Cash Flow for the year ending March 31, 2024 was USD 333.85 M, a 33.54% change year over year.
Cipla Limited Free Cash Flow for the year ending March 31, 2023 was USD 250.00 M, a -27.68% change year over year.
Cipla Limited Free Cash Flow for the year ending March 31, 2022 was USD 345.68 M, a -13.80% change year over year.
Cipla Limited Free Cash Flow for the year ending March 31, 2021 was USD 401.01 M, a 46.10% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Free Cash Flow	Operating Cash Flow	Capital Expenditure	Net Cash Used For Investing Activities

NSE: CIPLA.NS

Cipla Limited

CEO	Mr. Umang Vohra B.E., M.B.A.
IPO Date	Jan. 1, 1996
Location	India
Headquarters	Cipla House
Employees	27,764
Sector	🏥 Health Care
Industries Pharmaceuticals 🔬 Clinical Trials 💊 Drugstores & Retail Pharmacies

Description

Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, HIV, respiratory, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. It also provides respiratory products, including inhalers and nasal sprays, as well as other respiratory products consists of injectables and biosimilars. Cipla Limited has a licensing agreement with Merck & Co., Inc. for the manufacturing and distribution of Molnupiravir, an investigational oral antiviral drug; a license agreement with Eli Lilly and Company for the manufacture and commercialization of the drug baricitinib for Covid-19 indication; and collaborations with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for the clinical trial of the investigational oral anti-viral drug Molnupiravir. The company was incorporated in 1935 and is headquartered in Mumbai, India.